[go: up one dir, main page]

MA39411A - Synthèse de l'énantiomère de la progestérone et ses intermédiaires - Google Patents

Synthèse de l'énantiomère de la progestérone et ses intermédiaires

Info

Publication number
MA39411A
MA39411A MA039411A MA39411A MA39411A MA 39411 A MA39411 A MA 39411A MA 039411 A MA039411 A MA 039411A MA 39411 A MA39411 A MA 39411A MA 39411 A MA39411 A MA 39411A
Authority
MA
Morocco
Prior art keywords
intermediaries
progesterone
enantiomer
enterprogesterone
intermediates
Prior art date
Application number
MA039411A
Other languages
English (en)
Inventor
John W Cran
Daniel E Levy
Original Assignee
Prevacus Inc
The Florida State Univ Research Foundation Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prevacus Inc, The Florida State Univ Research Foundation Incorporated filed Critical Prevacus Inc
Publication of MA39411A publication Critical patent/MA39411A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0805—Compounds with Si-C or Si-Si linkages comprising only Si, C or H atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5022—Aromatic phosphines (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
    • C07J15/005—Retrosteroids (9 beta 10 alfa)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C07J75/005—Preparation of steroids by cyclization of non-steroid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention concerne la synthèse d'ent-progestérone et de ses intermédiaires.
MA039411A 2014-09-17 2015-09-17 Synthèse de l'énantiomère de la progestérone et ses intermédiaires MA39411A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051900P 2014-09-17 2014-09-17

Publications (1)

Publication Number Publication Date
MA39411A true MA39411A (fr) 2016-03-24

Family

ID=55533837

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039411A MA39411A (fr) 2014-09-17 2015-09-17 Synthèse de l'énantiomère de la progestérone et ses intermédiaires

Country Status (20)

Country Link
US (1) US20160108081A1 (fr)
EP (1) EP3194418B1 (fr)
JP (1) JP2017535596A (fr)
CN (1) CN108064228A (fr)
AR (1) AR101951A1 (fr)
AU (1) AU2015317651A1 (fr)
BR (1) BR112017005167A2 (fr)
CA (1) CA2961628A1 (fr)
CL (1) CL2017000645A1 (fr)
EA (1) EA201790428A1 (fr)
ES (1) ES2910225T3 (fr)
IL (1) IL251237A0 (fr)
MA (1) MA39411A (fr)
PH (1) PH12017500499A1 (fr)
SG (1) SG11201702115SA (fr)
TN (1) TN2017000088A1 (fr)
TW (1) TW201619183A (fr)
UY (1) UY36306A (fr)
WO (1) WO2016044558A1 (fr)
ZA (1) ZA201701976B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358248A (zh) * 2013-03-15 2016-02-24 佛罗里达州立大学研究基金有限公司 对映黄体酮及其中间产物的合成
IT201700004904A1 (it) 2017-01-18 2018-07-18 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 9β,10α-PROGESTERONE (RETROPROGESTERONE)
GB202203328D0 (en) 2022-03-10 2022-04-27 Givaudan Sa Organic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2623071A (en) * 1948-05-13 1952-12-23 Synor Res Lab Inc Preparation of substituted cyclopentenones
JPS4926214A (fr) * 1971-07-14 1974-03-08
US4189431A (en) * 1975-08-04 1980-02-19 The Board of Trustees of Leland Stanford Junior University Alkinyl terminating groups in biogenetic-like cyclizations to steroids
JP2001247562A (ja) * 2000-03-07 2001-09-11 Daicel Chem Ind Ltd アミド化合物及びその製造方法
EP2260052A4 (fr) * 2008-02-26 2013-01-16 Univ Emory Analogues stéroïdiens utilisés en neuroprotection
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
HUE029002T2 (en) * 2010-12-17 2017-01-30 Mitsubishi Tanabe Pharma Corp Continuous aricyclic compounds
CN105358248A (zh) * 2013-03-15 2016-02-24 佛罗里达州立大学研究基金有限公司 对映黄体酮及其中间产物的合成

Also Published As

Publication number Publication date
TW201619183A (zh) 2016-06-01
JP2017535596A (ja) 2017-11-30
EP3194418B1 (fr) 2021-12-15
WO2016044558A1 (fr) 2016-03-24
UY36306A (es) 2016-04-29
AU2015317651A1 (en) 2017-04-06
CL2017000645A1 (es) 2018-09-14
US20160108081A1 (en) 2016-04-21
PH12017500499A1 (en) 2017-08-30
ZA201701976B (en) 2019-06-26
EA201790428A1 (ru) 2017-08-31
EP3194418A1 (fr) 2017-07-26
TN2017000088A1 (en) 2018-07-04
CN108064228A (zh) 2018-05-22
BR112017005167A2 (pt) 2018-06-19
SG11201702115SA (en) 2017-04-27
IL251237A0 (en) 2017-05-29
CA2961628A1 (fr) 2016-03-24
AR101951A1 (es) 2017-01-25
EP3194418A4 (fr) 2018-12-12
ES2910225T3 (es) 2022-05-12

Similar Documents

Publication Publication Date Title
MA40576A (fr) Anticorps et immunoconjugués anti-her2
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
ZA201902141B (en) Acid-alpha glucosidase variants and uses thereof
EP4335874A3 (fr) Anticorps anti-hla-g et leur utilisation
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MA53356A (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
ZA201902140B (en) Acid-alpha glucosidase variants and uses thereof
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
TWD179057S (zh) 充電器
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
MX377663B (es) Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
IN2013MU00848A (fr)
MX382864B (es) Formulaciones de anticuerpos cristalinos.
IN2015CH01182A (fr)
MA39126B1 (fr) Synthèse d'enantiomère de progestérone et d'intermédiaires de celui-ci
MA39411A (fr) Synthèse de l'énantiomère de la progestérone et ses intermédiaires
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
MA39355B2 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.
MA38492A1 (fr) Anticorps et immunoconjugués anti-b7-h4